|
US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
|
KR0182801B1
(ko)
|
1991-04-16 |
1999-05-01 |
아만 히데아키 |
고체 분산체의 제조방법
|
|
CZ282760B6
(cs)
|
1991-11-22 |
1997-09-17 |
Procter And Gamble Pharmaceuticals, Inc. |
Risedronátové prostředky se zpožděným uvolňováním
|
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
DE69332291T2
(de)
|
1992-10-16 |
2003-07-31 |
Nippon Shinyaku Co., Ltd. |
Verfahren zur herstellung von wachsmatrizes
|
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
JPH11505258A
(ja)
|
1995-05-17 |
1999-05-18 |
セダーシナイ メディカル センター |
小腸における消化および吸収を改善させる脂肪酸を含む組成物
|
|
DE19624292A1
(de)
|
1996-06-18 |
1998-01-02 |
Merckle Gmbh |
Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
|
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
|
WO2005121112A1
(ja)
|
2004-06-10 |
2005-12-22 |
Torii Pharmaceutical Co., Ltd. |
６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物
|
|
US20080305169A1
(en)
|
2006-05-26 |
2008-12-11 |
Japan Tobacco Inc. |
Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
|
|
CN101765582A
(zh)
|
2007-04-26 |
2010-06-30 |
奥斯拜客斯制药有限公司 |
氘标记的氯胺酮
|
|
US8791077B2
(en)
*
|
2008-05-22 |
2014-07-29 |
Astrazeneca Ab |
Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
|
|
JP5325065B2
(ja)
|
2009-09-30 |
2013-10-23 |
株式会社富士薬品 |
新規フェノール誘導体
|
|
IT1400609B1
(it)
*
|
2010-05-10 |
2013-06-14 |
Menarini Int Operations Lu Sa |
Associazione di inibitori della xantina ossidasi e metformina e loro uso.
|
|
US10005750B2
(en)
|
2010-10-06 |
2018-06-26 |
J-Pharma Co., Ltd. |
Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
|
|
US20150031768A1
(en)
|
2011-08-19 |
2015-01-29 |
The Trustees Of Princeton University |
C-halogen bond formation
|
|
US9060987B2
(en)
|
2011-11-04 |
2015-06-23 |
Cymabay Therapeutics, Inc. |
Methods for treating gout flares
|
|
US9962362B2
(en)
|
2012-03-29 |
2018-05-08 |
Children's Hospital Medical Center |
Use of small molecule inhibitors targeting EYA tyrosine phosphatase
|
|
WO2013152860A2
(en)
|
2012-04-11 |
2013-10-17 |
Dutalys Gmbh |
Improved antibody light chains
|
|
JO3754B1
(ar)
|
2012-06-04 |
2021-01-31 |
Pharmacyclics Llc |
أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
|
|
CN104717980A
(zh)
|
2012-08-14 |
2015-06-17 |
米纳瓦生物技术公司 |
干细胞增强疗法
|
|
JP2016500367A
(ja)
|
2012-12-05 |
2016-01-12 |
デュタリス ゲーエムベーハー |
デュアルターゲティング
|
|
WO2014113407A2
(en)
|
2013-01-16 |
2014-07-24 |
Children's Hospital Medical Center |
Use of small molecule inhibitors targeting eya tyrosine phosphatase
|
|
WO2014149789A1
(en)
|
2013-03-15 |
2014-09-25 |
Janssen Pharmaceutica Nv |
Combination of canagliflozin and probenecid for the treament of hyperuricemia
|
|
WO2014194226A2
(en)
|
2013-05-31 |
2014-12-04 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods of treatment and compositions with xanthine oxidase inhibitors
|
|
WO2015134467A1
(en)
|
2014-03-05 |
2015-09-11 |
The Trustees Of Princeton University |
Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
|
|
CN107001356B
(zh)
|
2014-07-31 |
2019-09-03 |
默克专利有限公司 |
用于神经退化性疾病的中氮茚衍生物
|
|
CN104262305B
(zh)
|
2014-09-16 |
2016-06-08 |
东北制药集团股份有限公司 |
一种苯溴马隆晶型a及其制备方法
|
|
CN104311516B
(zh)
|
2014-09-16 |
2017-01-11 |
东北制药集团股份有限公司 |
一种苯溴马隆晶型b及其制备方法
|
|
EP3484862B1
(en)
*
|
2016-07-18 |
2021-09-01 |
Arthrosi Therapeutics, Inc. |
Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
|
|
WO2018090921A1
(zh)
|
2016-11-16 |
2018-05-24 |
江苏新元素医药科技有限公司 |
Urat1抑制剂及其应用
|
|
KR101964435B1
(ko)
|
2016-12-14 |
2019-04-01 |
주식회사 엘지화학 |
헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자
|
|
US20210130312A1
(en)
|
2018-04-03 |
2021-05-06 |
Children's Hospital Medical Center |
Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
|
|
MX2021003845A
(es)
|
2018-10-01 |
2021-05-27 |
Astrazeneca Ab |
Composiciones para reducir el acido urico serico.
|
|
SG11202105743RA
(en)
|
2018-12-06 |
2021-06-29 |
Arthrosi Therapeutics Inc |
Methods for treating or preventing gout or hyperuricemia
|
|
KR102946486B1
(ko)
|
2018-12-06 |
2026-03-31 |
아쓰로시 테라퓨틱스, 인크. |
통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
|
|
WO2020232156A1
(en)
|
2019-05-14 |
2020-11-19 |
Arthrosi Therapeutics, Inc. |
Compound for treating gout or hyperuricemia
|
|
CN112952564B
(zh)
|
2019-12-25 |
2022-04-22 |
华为数字能源技术有限公司 |
配电模块及通信电源系统
|
|
KR20230024354A
(ko)
|
2020-06-10 |
2023-02-20 |
아쓰로시 테라퓨틱스, 인크. |
만성 신장 질환을 치료 또는 예방하는 방법
|
|
CN112729156A
(zh)
|
2020-12-24 |
2021-04-30 |
上海智能制造功能平台有限公司 |
一种人体数字化测量装置的数据拼接及系统标定方法
|
|
CN114697265A
(zh)
|
2020-12-29 |
2022-07-01 |
华为技术服务有限公司 |
一种报文处理方法及装置
|
|
TW202330485A
(zh)
|
2021-12-02 |
2023-08-01 |
美商安索治療公司 |
用於治療或預防痛風或高尿酸血症之化合物的結晶形式
|
|
WO2023125667A1
(en)
|
2021-12-30 |
2023-07-06 |
Arthrosi Therapeutics, Inc. |
Preparation of a compound for the treatment of gout or hyperuricemia
|